and Application of Risk-Benefit Assessment of Medicines, Washington, DC. Insitute of Medicine Committee on the Assessment of the US Drug Safety System.

Randall, B. 2001. The US Drug Approval Process: A Primer. [Online]. Available: [accessed June 27, 2005].

Ray WA, Stein CM. 2006. Reform of drug regulation—beyond an independent drug-safety board. N Engl J Med 354(2):194-201.

Rodriguez EM, Staffa JA, Graham DJ. 2001. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf 10(5):407-410.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women’s Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321-333.

Smith C, Cowan C, Sensenig A, Catlin A, the Health Accounts Team. 2005. Health spending growth slows in 2003. Health Aff 24(1):185-194.

Weiss Smith S. 2006. Summary of Issues: January 17, 2006 IOM Workshop. Paper Commissioned by the IOM Committee on the Assessment of the US Drug Safety System. Washington, DC.

Wolfe S. 2004. Take Drugs Off the Market. [Online]. Available: [accessed March 8, 2005].

Wolfe S, Public Citizen’s Health Research Group. 2005. Statement by Sidney M. Wolfe, M.D., Director, Public Citizen’s Health Research Group, at the Public Hearing on CDER’s Current Risk Communication Strategies for Human Drugs, December 7, 2005. Washington, DC.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement